TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power Sells 10,021 Shares

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

TG Therapeutics Price Performance

TGTX remained flat at $28.00 on Tuesday. The company’s stock had a trading volume of 2,930,795 shares, compared to its average volume of 2,870,394. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84. The stock’s 50-day moving average is $31.26 and its 200 day moving average is $25.16. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market cap of $4.36 billion, a PE ratio of -279.97 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter last year, the company earned $0.73 EPS. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Institutional Trading of TG Therapeutics

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in TG Therapeutics by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock worth $8,960,000 after purchasing an additional 59,523 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of TG Therapeutics by 32.3% during the 2nd quarter. Principal Financial Group Inc. now owns 46,817 shares of the biopharmaceutical company’s stock worth $833,000 after buying an additional 11,443 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of TG Therapeutics by 1.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 186,994 shares of the biopharmaceutical company’s stock valued at $3,327,000 after buying an additional 2,360 shares during the period. Rhumbline Advisers boosted its stake in shares of TG Therapeutics by 7.8% in the second quarter. Rhumbline Advisers now owns 215,055 shares of the biopharmaceutical company’s stock valued at $3,826,000 after buying an additional 15,582 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in TG Therapeutics by 24.6% in the second quarter. Victory Capital Management Inc. now owns 26,212 shares of the biopharmaceutical company’s stock worth $466,000 after acquiring an additional 5,169 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TGTX shares. StockNews.com downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 22nd. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright lifted their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.